Navigation Links
Neuralstem Reports Second Quarter Financial Results and Highlights
Date:8/14/2008

ROCKVILLE, Md., Aug. 14 /PRNewswire-FirstCall/ -- Neuralstem Inc. (Amex: CUR) today reported financial results for the three months ended June 30, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20061221/DCTH007LOGO )

For the second quarter of 2008, the Company reported a net loss of $2,957,672, or $(0.09) per share, compared to a net loss of $1,798,911 or $(0.06) per share, for the comparable 2007 period. Net loss attributable to common stockholders for the first six months of 2008 was $5,232,124 or $(0.16) per share, compared to $2,748,153, or $(0.10) per share, for the comparable periods in 2007. The increase in net loss year to year was due to an increase in non cash stock-based compensation expense, salaries, and legal fees. The Company used $1.4 million of cash in the second quarter and $3.2 million of cash in the first half of the year. The cash balance at the end of the first half was $6.9 million.

Result of Operations for the Three Months ending June 30, 2008 and 2007:

Revenues for the three months ended June 30, 2008 and 2007 were $0 and $78,499 respectively as 2007 included funding from a grant which has ended.

Research and development expenses for the three months ended June 30, 2008 and 2007 were $1,633,728 and $744,149, respectively. The increase in expenses in current period consists mainly of payroll and payroll related expenses, stock-based compensation expense, research supplies and costs incurred in connection with preparing for clinical trials.

General and administrative expenses for the three months ended June 30, 2008 and 2007 were $1,318,708, and $1,178,015, respectively. The principal increase in expenses in 2008 versus 2007 is a result of increased stock-based compensation expenses, payroll and legal (both patent and corporate), including legal expense related to patent work and litigation.

Other non-operating income for the three months ended June 30, 2008 and 2007 were $10,545, and $58,058 respectively. The decrease in 2008 relates to a reduction in short term interest rates which drives income derived from our cash balance.

Net loss for the three months ended June 30, 2008 and 2007 was $2,957,672 and $1,798,911, respectively.

Results of Operations for the Six Months ending June 30, 2008 and 2007:

There were no revenues for the six month period ending June 30, 2008. In the same period in the prior year the Company had $260,324 from a licensing agreement, sales of tissue products, and the substantial completion of a discontinued National Institute of Health grant.

Research and development expenses for the six month periods ending June 30, 2008 and 2007 were $2,832,572 and $1,626,639, respectively. The increase in expenses in current period consists mainly of payroll and payroll related expenses, stock based compensation expense, research supplies and costs incurred in connection with our current effort to produce preclinical data which results in animal surgeries, manufacturing of cells, and in vitro characterization of cells which includes testing and cell quality control.

General and administrative expenses for the six month periods ending June 30, 2008 and 2007 were $2,401,877 and $1,432,167, respectively. The principal increase in expenses in the current period versus the same period last year is a result of increases in professional fees and expenses related to accountants, legal and business advisors, stock based compensation expense.

Non-operating income for the six month period ending June 30, 2008 and 2007 were $31,862, and $76,961, respectively. The largest factor influencing the reduction in 2008 is the drop in short term interest rates on our cash balances.

Highlights 2008

In July the Company notified CJ CheilJedang Corporation (CJ) that Neuralstem will exercise its right to commence negotiations with CJ concerning the potential addition of China to the list of Asian countries for which CJ has purchased an option to negotiate for the exclusive license to Neuralstem's stem cell-products and technology. In February 2008, CJ purchased options to negotiate exclusive licenses for: Korea, Indonesia, Philippines, Malaysia, Singapore and Vietnam. CJ CheilJedang Corporation is a subsidiary company of CJ Group whose core businesses consists of Food & Food Services, Bio Pharma, Entertainment Media, and Home Shopping & Logistics.

In August, Dr. Thomas Hazel will be rejoining the Company as Senior Vice President, Research. He will be working with Dr. Karl Johe, Neuralstem's Chairman and Chief Science Officer, to manage the Company's upcoming clinical trial for ALS (Amytrophic Lateral Sclerosis, or Lou Gehrig's disease), and complete development of Neuralstem's small molecule neurogenesis compound targeted to treat depression.

The Company neared completion of the pre clinical package for the Company's stem cell derived treatment for ALS.

The Company has begun manufacturing a batch of Neuralstem's small molecule neurogenesis treatment using "Good Manufacturing Practice" procedures. The compound will be used in required safety testing prior to human trials for the drug.

In April the European Patent Office granted Neuralstem a European patent EP0915968, covering the "Isolation, Propagation and Directed Differentiation of Stem Cells from Embryonic and Adult Central Nervous System of Mammals." The European patent has been validated in several European countries including France, Germany, Ireland, Spain, Sweden, Switzerland and the United Kingdom.

STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended June 30,

2008 2007

Revenues $- $ 78,499

Operating expenses

Research and development costs 1,633,729 744,149

General, selling and administrative expense 1,318,708 1,178,015

Depreciation and amortization 15,780 12,981

Total 2,968,217 1,935,145

Operating loss (2,968,217) (1,856,646)

Non-operating income (expense)

Interest Income 10,545 58,058

Interest expense - (323)

Net loss $(2,957,672) $(1,798,911)

Net loss per share, basic and dilutive $(0.09) $(0.06)

Average number of shares of common stock

outstanding 32,109,858 29,024,012

BALANCE SHEETS

June 30, December 31,

2008 2007

(Unaudited)

ASSETS

CURRENT ASSETS

Cash $6,966,587 $7,403,737

Prepaid expenses 80,702 130,719

Total current assets 7,047,289 7,534,456

Property and equipment, net 175,238 136,920

Other assets 49,272 43,271

Intangible assets, net 127,228 111,406

Total assets $7,399,027 $7,826,053

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable and accrued expenses 936,110 1,016,699

STOCKHOLDERS' EQUITY

Preferred stock - -

Common stock 321,513 314,106

Additional paid-in capital 57,029,525 52,151,245

Accumulated deficit (50,888,121) (45,655,997)

Total stockholders' equity 6,462,917 6,809,354

Total liabilities and stockholders' equity $7,399,027 $7,826,053

About Neuralstem

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Major Central Nervous System diseases targeted by the Company with research programs currently underway include: Ischemic Paraplegia, Traumatic Spinal Cord Injury and ALS. The company's cells have extended the life of rats with ALS (Lou Gehrig's disease) as reported the journal TRANSPLANTATION, in collaboration with Johns Hopkins University researchers, and also reversed paralysis in rats with Ischemic Spastic Paraplegia, as reported in NEUROSCIENCE on June 29, 2007, in collaboration with researchers at University of California San Diego. The Company expects to file its first IND (Investigational New Drug) application with the FDA for ALS in the fall.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10- KSB for the year ended December 31, 2007 and the quarterly report on form 10-Q for the period ended June 30, 2008.


'/>"/>
SOURCE Neuralstem Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Neuralstem Fills Key Product Development Position
2. Neuralstem Responds to New StemCells, Inc. Lawsuit
3. Neuralstem Sues StemCells, Inc. Over New Patent
4. Neuralstem Inc. Announces Strategic Investment by Korean CJ CheilJedang Corporation
5. Patent Office Rules in Neuralstems Favor in Dispute with StemCells, Inc.
6. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
7. Neuralstem Shares Accepted for Trading on Amex(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. Senetek PLC Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... CA (PRWEB) , ... June 27, 2016 , ... ... for clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT ... care circle with the physician and clinical trial team. , Using the CONSULT module, ...
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Researchers at ... most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are the ... read it now. , Diagnostic biomarkers are signposts in the blood, lung fluid ...
Breaking Biology Technology:
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
Breaking Biology News(10 mins):